Navigation Links
Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
Date:1/9/2012

BANNOCKBURN, Ill., Jan. 9, 2012  /PRNewswire/ -- Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion.

"Today's announcement represents another major milestone for Pinnacle Biologics. After completing the acquisition of the Global Photo Dynamic Therapy ("PDT") Business from Aptalis Pharma early last year, Pinnacle continues the process of solidifying its presence in the US Oncology Field, for particularly aggressive forms of cancer, expanding its presence in Europe and emerging markets, and completing the clinical work toward supporting regulatory and clinical development of new indications for PDT globally," said Guillermo Herrera, Executive Chairman and CEO of Pinnacle. In addition, the company remains focused on targeting the acquisition of other specialty pharmaceutical revenue generating products to further accelerate growth and supplement the existing business.

"Pinnacle exemplifies a new model of bio-pharmaceutical companies, with proven management, demonstrated ability to execute, and products with clear upside potential due to expansion of use in existing indications, potential for expansion into new and exciting indications in unmet clinical areas, and global expansion beyond the US and Western European markets," said Patrick Keenan, Chief Counsel and Strategist of Numoda Capital Innovations.

"The proceeds from this financing round coupled with the positive cash flows already generated by the company will be used to support Phase 3 Clinical Trials in cholangiocarcinoma, laryngeal tracheal cancer, and mesothelioma, plus the enhancement of commercial activities to optimize revenue in the current businesses of the company," said Gary Parks CFO of Pinnacle.

ABOUT PINNACLE BIOLOGICS:

Pinnacle Biologics specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. This is accomplished through licensing and acquisition of specialty pharmaceuticals and medical devices. Our innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.

FORWARD LOOKING STATEMENT

Except for historical information contained herein, there are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved.                                                                                               

CONTACT:

Guillermo Herrera
Executive Chairman
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695

www.pinnaclebiologics.com
www.photofrin.com


'/>"/>
SOURCE Pinnacle Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Syndication Inc. Seeks DIRECTOR OF TECHNICAL ENGINEERING for PINNACLE ENERGY - Its New Alternative Energy Subsidiary
2. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
3. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
4. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
5. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
6. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
7. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
8. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... --  ViaCyte, Inc. , a privately-held regenerative medicine company ... for the treatment of diabetes in clinical-stage development, today ... 2016, the Global Stem Cell Event, is taking place ... Francisco.    ... Focus Session: Tools for Basic and Applied Stem Cell ...
(Date:6/22/2016)... ... June 22, 2016 , ... ... spotlight on immigrant achievements and contributions to North Texas and the nation, recently ... from the immigrant community to the civic and economic vitality of North Texas. ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):